Skip to main content
VBIO
NASDAQ Life Sciences

Valion Bio Fires General Counsel; Entolimod Advances to Fully Funded AFRRI Efficacy Study

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.585
Mkt Cap
$1.186M
52W Low
$0.524
52W High
$67.5
52W Position info
12% above low
Off High info
99% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

VBIO is trading near its 52-week low of $0.524 (12% above the low) on light trading volume (0.1× avg).

Summary

Valion Bio disclosed the termination of General Counsel Melinda Lackey effective October 30, 2026, with a $26,750 severance, and announced that AFRRI will run a fully funded Entolimod efficacy study in GI-ARS with top-line results expected in early December.


Key Events · Executive and Board Changes · VBIO

  • General Counsel Terminated

    Valion notified Melinda Lackey, General Counsel and SVP of Legal Affairs, of termination on October 27, 2026, effective October 30, 2026.

  • Severance Terms Disclosed

    Separation Agreement dated October 31, 2026 provides a $26,750 gross lump-sum payment plus COBRA premiums through November 30, 2026; Lackey forfeits unvested equity and releases all claims.

  • Open Legal Matters Handed Off

    The agreement requires Lackey to transfer a list of open matters including the Bexar County lawsuit (Snell), the CG Capital / Rich matter, patent counsel matters (Dentons, Launchpad, Snell), the Handley proxy item and pending 8-Ks.

  • Entolimod Moves to Efficacy Study

    AFRRI will evaluate Entolimod in a GI-ARS therapeutic efficacy model, fully funded by NIAID/RNCP under an Interagency Agreement with USU/AFRRI; top-line survival results are anticipated in early December.


Analysis · VBIO · Life Sciences

Valion is losing its top legal officer at a moment when it is juggling a Bexar County lawsuit, a CG Capital/Rich matter, patent counsel work and a proxy fight — the separation agreement itself lists those open matters as handoff items. The $26,750 severance is trivial in dollar terms, but the timing and the breadth of open legal matters make the departure a governance concern rather than a routine exit. The offsetting news is that NIAID's Radiation and Nuclear Countermeasures Program elected to move Entolimod into a fully funded therapeutic efficacy study at AFRRI, with top-line survival data expected in early December. That study costs Valion nothing and produces the next binary readout on its lead asset, which matters for a company that previously disclosed going-concern doubt and cash of just $2.1M at June 30.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VBIO was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.52 to $67.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VBIO - Latest Insights

VBIO
Nov 05, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.502
Real-time Price: $0.5126 info
Change: +$0.0106 (+2%) info
Market Cap: $1.105M info
VBIO
Oct 30, 2026, 7:50 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.6373
Real-time Price: $0.5126 info
Change: -$0.1247 (-20%) info
Market Cap: $1.105M info
VBIO
Oct 29, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6758
Real-time Price: $0.5126 info
Change: -$0.1632 (-24%) info
Market Cap: $1.105M info
VBIO
Oct 27, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.765
Real-time Price: $0.5126 info
Change: -$0.2524 (-33%) info
Market Cap: $1.105M info
VBIO
Oct 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.920
Real-time Price: $0.5126 info
Change: -$0.4074 (-44%) info
Market Cap: $1.105M info